Myriad Genetics calls on Scotus to reject petition from ruling finding DNA molecules patent-eligible According to Myriad Genetics, Inc., the U.S. Supreme Court should not grant review in Association for Molecular Pathology v. Myriad Genetics, Inc. Details about the Federal Circuit Court of Appeals decision on remand from the lawsuit’s previous sojourn before the U.S. Supreme Court appear in Issue 41 of this Bulletin. The American Civil Liberties Union (ACLU) has requested that the Court review the Federal Circuit’s decision.